

June and July 2026 updates to prior authorizations and post service claim edits

Security Health Plan requires prior authorization (PA) and post service claim edits (PSCE) on office-administered, medically billed medications to ensure coverage and appropriate payment for those services. The following changes will occur to our medical pharmacy program administered by Prime Therapeutics.

The following drugs will be removed from PA and/or PSCE effective June 1.

- Akynzeo IV
- Aloxi
- Aphexda
- Cosela
- Emend
- Faslodex
- Feraheme
- Focinvez
- Fosaprepitant
- Fusilev
- Injectafer
- Khapzory
- Leukine
- Monoferric
- Mozobil
- Posfrea
- Retisert
- Supprelin LA

The following drugs will transition from Prime Therapeutics to Eviti management effective June 1:

- Bizengri
- Tecelra

The following drugs will move from requiring PA to benefit exclusion effective June 1. We will honor existing prior authorizations; new requests will follow the benefit exclusion.

- Amondys 45
- Elevidys
- Encelto
- Exondys 51
- Kebilidi
- Kisunla*
- Lantidra
- Qalsody
- Viltepso
- Vyondys-53

*Kisunla will remain covered with PA for the Medicare line of business.

The following drugs will be moving from PSCE to also requiring PA effective July 1.

- Aralast NP
- Glassia
- Prolastin-C
- Remodulin
- Veletri/Flolan
- Zemaira

This list includes the updates for June and July 2026. Going forward, Prime Therapeutics – Security Health Plan’s specialty pharmacy medication partner – will manage prior authorization. Please call (800) 424-8243 or visit their website for details.

You can review the full list of all medications requiring a prior authorization or post service claim edit on [Security Health Plan’s website](#). Contact our provider experience team with questions at **(800) 548-1224**.